New results help predict treatment response in colorectal cancer

September 17, 2008

Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.

At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm, Dr. Christos Karapetis from Flinders University in Australia reports on a genetic analysis of 394 patients who took part in a phase III study comparing the monoclonal antibody cetuximab with best supportive care.

The latest analysis compared the effect of mutations in the K-Ras gene on overall survival and progression-free survival. The gene encodes a protein that is a key component of cellular signalling pathways, conveying extracellular growth signals from the cell surface to the nucleus. When growth factors bind to cell surface receptors, including epidermal growth factor receptor (EGFR), K-Ras is temporarily activated, facilitating regulated cell growth and proliferation.

The K-Ras gene is mutated in up to 35% of colorectal cancers. These mutations keep K-Ras stuck in its active form, switching on signalling without the requirement for EGFR stimulation.

Dr. Karapetis and colleagues found that patients with mutated forms of K-Ras had a median overall survival of 4.6 months when treated with cetuximab, and 4.5 moths with supportive care. In contrast, among those with wild-type forms, overall survival jumped to 9.5 months when treated with cetuximab, compared to 4.8 months with best supportive care.

The results show that determining K-Ras mutation status should be considered a new standard of care for selecting patients for targeted therapies against EGFR, the authors say.

Also at the congress, Professor Eric Van Cutsem from University Hospital Gasthuisberg, Leuven in Belgium will present data on the impact of K-Ras mutations from the Crystal study, in which patients were randomized to either the chemotherapy combination "FOLFIRI" or FOLFIRI plus cetuximab, in first line metastatic colorectal cancer.

Professor Van Cutsem recently reported that the combination of cetuximab and FOLFIRI significantly improves progression free survival and response rate in patients with a K-Ras wild type. In Stockholm he will present new data on survival in the Crystal trial.

"Overall survival in all patients included in the trial was identical in both treatment arms. There was however a strong trend towards a longer survival in patients with a K-Ras wild type tumor treated with cetuximab/FOLFIRI," he said. The median survival was 24.9 months for patients who received the cetuximab combination, versus 21.0 months (HR: 0.84). The overall survival results in patients with K-Ras mutant tumors did not differ in the two study arms.

In another study, Dr. Miriam Koopman from the University Nijmegen Medical Centre St. Radboud in The Netherlands, reports that the number of tumor cells found circulating in the blood of patients with advanced colorectal cancer is another valuable predictor of survival.

Her group studied 467 patients who were being treated within a prospective clinical trial (CAIRO2 of the Dutch Colorectal Cancer Group) with chemotherapy plus bevacizumab, with or without the addition of cetuximab. In each patient they measured levels of circulating tumor cells before treatment, and at different stages during treatment.

"Circulating tumor cell (CTC) level might be an indicator of the aggressiveness of disease," Dr. Koopman explained. "Thus, a high CTC level before initiating therapy in metastatic colorectal cancer patients is an inferior prognostic factor in our study."

The results show that the median progression-free survival time for patients with less than three CTC in every 7.5mL of blood was 10.5 months, compared to 8.2 months for those with three or more. Furthermore the median overall survival time for patients with less than three CTC in every 7.5mL of blood was 22.2 months, compared to 13.7 months for those with three or more.

"In our study CTC in metastatic colorectal cancer patients proves to be an early prognostic marker," Dr. Koopman said. "Prospective trials are needed to investigate whether a change in therapy based on CTC is beneficial."

European Society for Medical Oncology

---

---

	American Cancer Society's Complete Guide to Colorectal Cancer by American Cancer Society (Author), Bernard Levin (Editor), Terri Ades (Editor), Katie Couric (Editor) Created by a prestigious panel of experts, this new book offers comprehensive coverage of colorectal cancer, the second most prevalent form of cancer in the world, which, with proper screening, is almost entirely preventable. It provides up-to-date, essential information about the disease, including prevention, detection, diagnosis, treatment options, complementary and alternative therapies, coping, living well with cancer, caregiving, and much more. Throughout the text real cancer survivors offer their experience dealing with this disease, from diagnosis to treatment and beyond.
	ABC of Colorectal Cancer (ABC Series) by Annie Young (Editor), Richard Hobbs (Editor), David Kerr (Editor) Colorectal cancer is a common cause of morbidity and mortality in which prevention, screening and early detection are vital. Beginning with the patient perspective and following the patient pathway, this new second edition covers epidemiology and prevention, screening programmes, decision support networks, the role of primary care, and supportive care for patients with colorectal cancer.The ABC of Colorectal Cancer provides the core knowledge on clinical genetics, diagnosis, imaging, therapy and surgery options and the latest evidence based guidelines for treating and managing colorectal cancer patients within the multidisciplinary team. Highly illustrated and accessible, it covers the full spectrum of the disease to provide the basis to make a real difference to clinical management.This...
	Be a Survivor Colorectal Cancer Treatment Guide by Vladimir Lange (Author) Dr. Lange’s comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their cancer and treatment options. Annually, 150,000 Americans are told they have colorectal cancer, making it one of the top three most common cancers in the United States. Diagnosed early, colorectal cancer is treatable, often curable, and vey preventable. This resource covers all aspects of colorectal cancer—from diagnosis to recovery, including a chapter for the patient's spouse.
	What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope by Mark Bennett Pochapin (Author) - What Your Doctor May Not Tell You About Colorectal Cancer was published in Warner hardcover (0-446-53188-X) in 3/04. The book features a foreword by Katie Couric. - Dr. Pochapin made an appearance on the Today show in conjunction with the hardcover publication of this book. Previously, he had been chosen by Katie Couric to be the Medical Director of the Jay Monahan Center for Gastrointestinal Health, named in honor of Ms. Couric's late husband. - The author is an associate professor of clinical medicine at the Weill Medical College of Cornell University and Chief of Gastrointestinal Endoscopy at New York Presbyterian Hospital's Weill Cornell Medical Center. - There are approximately 100,000 new colorectal cancer cases diagnosed annually, making it the second leading cause of...
	Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson (Author), Kathleen Ogle (Foreword) Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to making decisions and developing treatment plans. Also included are positive stories about life after cancer by 12 survivors.
	COPING WITH COLORECTAL CANCER by Crystal Night Books DESCRIPTION: Coping With Colorectal Cancer – the prevention and cure of the second leading cause of cancer deaths is dedicated to helping reduce the toll this disease takes on human lives. It aims at prevention by teaching people to avoid the risk factors that lead to the disease, to save lives through leading victims to early detection, and presenting treatment options to those patients diagnosed with the disease. Colorectal cancer, also commonly called bowel cancer, is caused by uncontrolled cell growth in the colon, rectum, or appendix. Actually the majority colorectal cancers occurs due to lifestyle and increasing age, while a minority of cases are associated with underlying genetic disorders. Colorectal cancer typically starts in the lining of the bowel and...
	Colorectal Cancer: Evidence-based Chemotherapy Strategies (Current Clinical Oncology) by Leonard B. Saltz (Editor) Recent advances in the understanding of the biology of colorectal cancer have radically transformed the treatment options available to clinicians, leaving textbooks written only two years ago completely out of date. This evidence-based and data-driven guide presents reviews of cutting-edge therapies for colorectal cancer, all articulated by leading experts in the field. This integrated and focused consideration of colorectal management includes reviews of cytotoxic chemotherapy, targeted biologic therapies, as well as updates on adjuvant chemotherapy for colon cancer and combined modality management of rectal cancers. Attention is also focussed on the role of potentially curative multi-modality management of liver metastases, with considerations of the role of liver resection and...
	Colorectal Cancer Screening (Clinical Gastroenterology) by Joseph Anderson MD (Editor), Charles Kahi MD (Editor) Colorectal Cancer Screening provides a complete overview of colorectal cancer screening, from epidemiology and molecular abnormalities, to the latest screening techniques such as stool DNA and FIT, Computerized Tomography (CT) Colonography, High Definition Colonoscopes and Narrow Band Imaging. As the text is devoted entirely to CRC screening, it features many facts, principles, guidelines and figures related to screening in an easy access format. This volume provides a complete guide to colorectal cancer screening which will be informative to the subspecialist as well as the primary care practitioner. It represents the only text that provides this up to date information about a subject that is continually changing. For the primary practitioner, information on the guidelines for screening...
	100 Questions & Answers About Colorectal Cancer by David Bub (Author), Susannah L. Rose (Author), W. Douglas Wong (Author) Whether You’Re A Newly Diagnosed Cancer Patient, A Survivor, Or A Friend Or Relative Of Either, This Book Offers Help. The Only Text To Provide The Doctor’S And Patient’S View, The Second Edition Is Updated With Authoritative, Practical Answers To Your Questions About Treatment Options, Post-Treatment Quality Of Life, Sources Of Support, And Much More. This Book Is An Invaluable Resource For Anyone Coping With The Physical And Emotional Turmoil Of This Frightening Disease. The Authors Consist Of Two Oncologic Surgeons And A Cancer Care Social Worker From Memorial Sloan-Kettering Cancer Center. Commentary From Actual Colon And Rectal Cancer Survivors Provides A Unique, “Insider’S” Perspective.
	Understanding Colorectal Cancer Anatomical Chart by Anatomical Chart Company (Author) Understanding Colorectal Cancer Anatomical Chart defines colorectal cancer and shows colorectal anatomy with the following pathologies: Adenocarcinoma of colon Circumferential carcinoma of the transverse colon Colonic polyps Adenocarcinoma of jejunum Adenocarcinoma of the rectosigmoid region The chart describes risk factors, signs and symptoms, screening and diagnostic tests, and treatment options, and illustrates and explains the stages of cancer.